The company remains entirely pre-revenue, with operating losses widening to $3.2 million in 2026Q1 as R&D expenses surged to $2.3 million.
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 7.28M | 4.24M | 365.06K | 19.3K |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 2.04M | 1.25M | 290.39K | 19.3K |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 5.24M | 2.99M | 0 | 0 |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 74.68K | 0 |
| Operating Income | -7.28M | -4.24M | -365.06K | -19.3K |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -1061.19% | -1791.71% | - |
| EBITDA | -7.19M | -4.16M | -290.39K | -17.48K |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -1332.47% | -1560.96% | - |
| D&A (Non-Cash Add-back) | 99.8K | 79.4K | 0 | 1.81K |
| EBIT | 136.23K | 0 | -290.39K | -19.3K |
| Net Interest Income | 1.36K | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | -9.89K | -8.54K | 0 | 0 |
| Other Income/Expense | 47.23K | 13.97K | 3.56K | 100 |
| Pretax Income | -7.24M | -4.23M | -361.51K | -19.2K |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -7.24M | -4.23M | -361.51K | -19.2K |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -1068.75% | -1783.04% | - |
| Net Income (Continuing) | -7.24M | -4.23M | -361.51K | -19.2K |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.17 | -0.01 | -0.00 |
| EPS Growth % | - | -1207.69% | - | - |
| EPS (Basic) | - | -0.17 | -0.01 | -0.00 |
| Diluted Shares Outstanding | 28.34M | 25.5M | 27.75M | 42M |
| Basic Shares Outstanding | 28.34M | 25.5M | 27.75M | 42M |
| Dividend Payout Ratio | - | - | - | - |
Insufficient capital for development
As indicated by historical financial filings, Curanex remains a pre-revenue entity with no active commercial segments, leaving the firm entirely dependent on external capital markets to fund its ongoing research and development initiatives across a broad and disparate pipeline of potential therapeutic indications.
The lack of revenue generation since at least 2024 underscores the company's status as a purely developmental-stage enterprise. Investors should recognize that the absence of top-line growth makes the firm's valuation entirely speculative and contingent upon future clinical milestones or potential licensing agreements.
Based on the most recent quarterly data, Curanex reported a significant surge in operating expenses, with R&D costs reaching $2.3 million in 2026Q1, reflecting a rapid acceleration in cash depletion as the company attempts to advance its botanical drug candidates through clinical trials.
The sharp increase in R&D spending relative to previous periods suggests an intensification of clinical activity or CMC development requirements. This rising cost structure, coupled with persistent administrative overhead, places immense pressure on the company's limited cash reserves and necessitates a clear path to non-dilutive funding.
According to reported income statements, Curanex's operating losses have widened significantly to $3.2 million in 2026Q1, demonstrating that the firm currently lacks any meaningful operating leverage as expenses scale rapidly without a corresponding increase in revenue or commercial progress to offset the burn.
The widening gap between operating expenses and the absence of gross profit indicates that the company is in a high-risk phase of capital consumption. Without a commercial product to provide scale, the current operating model appears unsustainable without frequent and potentially dilutive equity financing rounds.
While management emphasizes the proprietary nature of Phyto-N, the company's history of stagnation since 1996 suggests that the market may be correctly discounting the firm due to the extreme difficulty of scaling botanical manufacturing to meet rigorous FDA pharmaceutical standards for clinical consistency.
Short-sellers would likely focus on the 'botanical trap,' where agricultural variability creates insurmountable CMC hurdles that synthetic drug developers do not face. The company's broad, unfocused pipeline further suggests a lack of strategic discipline, which may lead to continued capital inefficiency and shareholder dilution.
Quick answers to the most common questions about buying CURX stock.
For fiscal year 2025, Curanex Pharmaceuticals Inc Common Stock (CURX) reported total revenue of $0.0M.
Curanex Pharmaceuticals Inc Common Stock (CURX) reported a net loss of $4.2M for the fiscal year ending 2025.